

**Registration**  
www.meeting-com.ch

Final  
Program



# 49th Annual Meeting Swiss Society of Nephrology

**Forum Fribourg, Granges-Paccot**  
December 7-8, 2017

Schweizerische Gesellschaft für Nephrologie  
Société Suisse de Néphrologie  
Società Svizzera di Nefrologia

## Symposia

**December 6, 2017**

Basics in Nephrology

**December 8, 2017**

Pflege in der Nephrologie / Soins en Néphrologie /  
Cure in Nefrologia

**NEPHRO**   
SWISS SOCIETY OF NEPHROLOGY

www.swissnephrology.ch

## Table of contents

Invitation 2017	3
Organization	4
General information	5
Program at a glance	8
Scientific Program – Basics in Nephrology	11
Scientific Program	12
Congress Dinner	22
Scientific Program & Pflege in der Nephrologie	23
Poster presentations	33
Speakers / Moderators	44
Exhibitors	47
Sponsored symposia in alphabetical order	48
Sponsors	49
SGN-SSN congress 2018	51

## Invitation 2017

Dear Colleagues,

It's a pleasure to invite you to the 49th annual meeting of the Swiss Society of Nephrology in Fribourg. This is the first time that we have the meeting at Fribourg and we hope that its central location will facilitate your participation.

The 2017 meeting is a continuum of the evolution of the precedent meetings. We are introducing this year the sponsored lectures which is another way to collaborate with our partners from the industry. We will have 4 sponsored lectures in addition to 5 satellite symposia which will cover different fields of interest in Nephrology.

The CME will be focused on peritoneal dialysis with some theoretical lectures but also some case reports to illustrate specific clinical situations.

The first state of the art lecture will be on thirst and will be given by Daniel Bichet from Montreal.

The second state of the art lecture on Home dialysis will be given by Eric Goffin, from Bruxelles.


As usual, we will have nephropathology and genetic inherited kidney diseases sessions and a session dedicated to NCCR, a consortium which is very active and a leader in renal physiology and pathophysiology.

Finally, we encourage you to attend to oral presentations and to poster sessions which are selected amongst the abstracts presented by our members. The scientific activity of the swiss nephrology community is outstanding and these sessions are organized to present this activity to SSN members. A poster walk is organised Thursday evening.

Friday, we will have nurses-oriented sessions. We have selected themes which concern both nephrology nurses and nephrologists.

I am eager to see you at Fribourg and to share with you the progresses that are done in our specialty.

Congress president SGN-SSN



Pierre-Yves Martin

## Organization

### Congress President

Pierre-Yves Martin, Geneva

### Scientific Committee

Patrizia Amico, Basel  
 Spyridon Arampatzis, Bern  
 Sophie De Seigneux, Geneva  
 Thomas Ernandez, Geneva  
 Eric Féraille, Geneva  
 Déla Golshayan, Lausanne  
 Karine Hadaya, Geneva  
 Nilufar Mohebbi, Zürich  
 Thomas Müller, Zürich  
 Belen Ponte, Geneva  
 Menno Pruijm, Lausanne  
 Fabien Stucker, Neuchâtel  
 Jean Villard, Geneva  
 Carsten Wagner, Zürich  
 Grégoire Würzner, Lausanne

### Board of the SGN-SSN

#### President 2016-2017

Pierre-Yves Martin, HUG, Geneva

#### President-elect

Uyen Huynh-Do, Inselspital, Bern

#### Secretary

Olivier Bonny, CHUV, Lausanne

#### Treasurer

Patrick Wilson, Hôpital du Jura, Delémont

#### Pediatric Nephrologist

Thomas J. Neuhaus, Kinderspital LUKS, Luzern

#### Dialysis Commission

Dominik E. Uehlinger, Inselspital, Bern

#### Board Members

Isabelle Binet, Kantonsspital, St. Gallen  
 Andreas Bock, Kantonsspital, Aarau  
 Olivier Devuyst, Institute of Physiology, Zürich  
 Daniel Fuster, Inselspital, Bern  
 Luca Gabutti, Ospedale Regionale, Bellinzona  
 Ann-Kathrin Schwarzkopf, Hirslanden Bern AG, Bern

## General information

### Congress venue

#### Forum Fribourg Expo Centre SA

Route du Lac 12, 1763 Granges-Paccot  
[www.forum-fribourg.ch](http://www.forum-fribourg.ch)

### Registration & congress secretariat

#### Meeting-com Congress Organisation

Rue des Pâquis 1, CH-1033 Cheseaux-sur-Lausanne  
 Online registration on: [www.meeting-com.ch](http://www.meeting-com.ch)  
 T +41 21 312 9261 – F +41 21 312 9263 – E [info@meeting-com.ch](mailto:info@meeting-com.ch)  
 Onsite registration also possible (onsite fee)

### Registration fees for SGN congress

	Early fee (before Nov. 1, 2017)	Late fee (Nov. 2-29, 2017)	Onsite fee (From Nov. 30, 2017)
Member SGN	CHF 230.00	CHF 270.00	CHF 300.00
Non-member SGN	CHF 280.00	CHF 320.00	CHF 360.00
Residents/Students*	CHF 150.00	CHF 180.00	CHF 210.00
Pflege in der Nephrologie	CHF 100.00	CHF 120.00	CHF 150.00
NCCR-Member	CHF 150.00	CHF 180.00	CHF 210.00

\* Confirmation of status for residents/student required to be sent to F 021 312 92 63 or to [nicole.giacomini@meeting-com.ch](mailto:nicole.giacomini@meeting-com.ch).

### Registration fees for Symposium 6.12.17

	Early bird fee (before Nov. 1, 2017)	Late fee (Nov. 2-29, 2017)	Onsite fee (From Nov. 30, 2017)
Basics in Nephrology	CHF 100.00	CHF 120.00	CHF 150.00

**Congress Dinner 7.12.17** CHF 90.00 (places limited)

### Included in the registration fees

Access to the scientific sessions, congress documents, certificate of participation, coffee breaks and lunches.  
**Accommodation not included.**

### Payment

Upon registration, you will receive a confirmation by email together with the banking details for the payment.  
 Payment by credit card upon registration is possible.

## General information

<b>Congress management</b>	Meeting.com Congress Organisation Mrs Nicole Giacomini Rue des Pâquis 1, CH-1033 Cheseaux-sur-Lausanne T +41 21 312 9161, F +41 21 312 9263 <a href="mailto:nicole.giacomini@meeting-com.ch">nicole.giacomini@meeting-com.ch</a> , <a href="http://www.meeting-com.ch">www.meeting-com.ch</a>
<b>Certificate of participation</b>	The certificate of participation will be sent in pdf form to the participants after the event.
<b>Cancellation</b>	Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CHF 60.00 for administrative costs. Thereafter no refund possible. Any registration made within the "early bird" time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.
<b>Industrial exhibition</b>	An industrial exhibition will take place at the Congress Venue. It will be open throughout the congress. Coffee (breaks) will be offered by exhibitors.
<b>Hotel booking</b>	Hotel reservation possible with Fribourg Tourismus on <a href="http://www.fribourgtourisme.ch">www.fribourgtourisme.ch</a> .
<b>Bus</b>	Forum Fribourg is reachable by bus nr 1, direction "Portes-de-Fribourg"
<b>WIFI</b>	Name SGN2017 Password Congress
<b>Parking</b>	A parking is available at Forum Fribourg. Daily tickets will be sold at the welcome desk at the price of CH 10.00/day

## General information

<b>Oral Presentations</b>	The abstracts accepted as oral communication will be presented in the Oral Parallel Presentations. <b>Speaking time : 8 min and 2 min discussion.</b>
<b>Posters</b>	The abstracts accepted as poster will be presented in the poster exhibition. <b>Dimensions of posters : height 120 cm x width 90 cm (portrait).</b>
<b>Posterwalk</b>	<b>There will be an organized Posterwalk on Thursday, December 7, 2017, from 17 h 45 to 18 h 30 where the highest rated posters in each category will receive the Poster Prize Award :</b> – Clinical Nephrology /Hypertension /Mineral/ Electrolytes – Basic Science /Genetics /Experimental Nephrology – Hemodialysis (HD)/Peritoneal Dialysis (PD) – Transplantation <b><a href="#">we thank each author to be present near his/her poster during the posterwalk</a></b>
<b>Poster Prize Awards</b>	will take place during the Congress Dinner on December 7, 2017.
<b>Registration</b>	<b>Authors presenting an accepted paper or poster must register to attend the meeting and pay the appropriate registration fee.</b>
<b>Credits</b>	Credits points will be given by the following societies : <b><a href="#">SGN-SSN Congress, December 7-8, 2017</a></b> SGN-SSN 16 credits SGAIM-SSMIG 10 credits <b><a href="#">Basics in Nephrology, December 6, 2017</a></b> SGN-SSN 4 credits SGAIM-SSMIG 4 credits
<b>Language</b>	Lectures in English, discussion in German, French or English. <b>The Symposium "Pflege in der Nephrologie" will be held in German, French and Italian</b>

# Program at a glance

## Wednesday, December 6, 2017

Special CME Symposium Basics in Nephrology Course	
Schedule	Room 3E
From 12.00	Registration
13.00-15.00	Plenary sessions
15.00-15.30	Coffee Break
15.30-17.30	Plenary sessions
17.30	End of Basics in Nephrology Course

# Program at a glance

## Thursday, December 7, 2017

Schedule	Room A	Room B
From 8.00	Registration	
09.45-09.50	<b>Welcome Address</b>	
09.50-10.45	<b>State of the Art Lectures</b>	
10.45-11.15	Coffee break – Visit of the exhibition – Poster viewing	
11.15-12.15	<b>Oral Parallel Presentations</b> Basic Science/Genetics/ Experimental Nephrology	<b>Oral Parallel Presentations</b> Transplantation
12.15-12.30	Short break	
12.30-13.15	<b>Satellite Lunch Symposium</b> Sponsored by <b>AMGEN</b>	
13.15-14.00	Standing lunch at the exhibition – Poster viewing	
14.00-15.00	Sponsored lecture by <b>ALEXION</b>	<b>Symposium NCCR Kidney.CH</b>
15.00-15.30	Coffee break – Visit of the exhibition	
15.30-16.15	<b>Parallel Satellite Symposium</b> Sponsored by <b>BAXTER</b>	<b>Parallel Satellite Symposium</b> Sponsored by <b>OTSUKA</b>
16.15-16.30	Short break	
16.30-17.40	<b>Parallel Symposium</b> <b>Nephropathology</b>	<b>Parallel Symposium</b> <b>WGIKD</b>
17.45-18.30	Posterwalk in the Exhibition	
19.45	WELCOME DRINK & CONGRESS DINNER with Poster Prize Awards	

# Program at a glance

## Friday December 8, 2017

Schedule	Room A	Room B	Room 3E
From 07.00	Registration		
07.45-09.15	<b>General assembly SGN-SSN</b>		
09.15-09.45	<b>The Swiss Dialysis Registry</b>		
09.45-10.00	<b>SGN-SSN Publication Award 2017</b>		
10.00-10.15	Short break		09.30-11.00 <b>Pflege in der Nephrologie</b>
10.15-11.00	<b>Satellite Symposium Sponsored by VIFOR</b>		
11.00-11.30	Coffee break – Visit of the exhibition – Poster viewing		
11.30-12.15	Sponsored lecture by <b>BAXTER</b>		11.30-12.15 <b>Pflege in der Nephrologie</b>
12.15-12.30	Short break		
12.30-13.15	<b>Satellite Symposium Sponsored by ASTELLAS</b>		12.30-13.15 <b>Pflege in der Nephrologie</b>
13.15-14.00	Standing lunch at the exhibition – Poster viewing		
14.00-15.00	<b>Oral Parallel Presentations</b> Clinical Nephrology / Hypertension / Mineral / Electrolytes	<b>Oral Parallel Presentations</b> Hemodialysis (HD) / Peritoneal Dialysis (PD)	
15.00-15.30	Coffee break – Visit of the exhibition – Poster viewing		
15.30-16.30	<b>Hot Topics</b>		
16.30	<b>Farewell</b>		

# Wednesday, December 6

Room 3E

## Satellite CME Symposium: Basics in Nephrology

### Peritoneal Dialysis

From 12.00	Registration
<b>13.00-13.40</b>	<b>Physiology of the peritoneal membrane</b> Olivier Devuyst, Zurich
<b>13.40-14.20</b>	<b>Peritoneal membrane transport characteristics and dialysis adequacy assessment in PD</b> Thomas Ernandez, Geneva
<b>14.20-15.00</b>	<b>Initial prescription in PD</b> Andreas Fischer, Lucerne
15.00-15.30	Coffee break
<b>15.30-16.10</b>	<b>Infectious complications in PD</b> Valérie Jotterand Drepper, Geneva
<b>16.10-16.50</b>	<b>Non-infectious complications in PD</b> Catherine Stoermann-Chopard, Geneva
<b>16.50-17.30</b>	<b>PD in practice (clinical cases discussion)</b> Georges Halabi, Lausanne
<b>17.30</b>	<b>End of Basics in Nephrology Course</b>

# Thursday, December 7

## Swiss Society of Nephrology Congress

From 08.00	Registration	
09.45	<b>Opening of the 49th Annual Meeting of the Swiss Society of Nephrology</b>	<b>Room A</b>
09.45-09.50	<b>Welcome Address</b> Pierre-Yves Martin, Geneva; Daniel Hayoz, Fribourg	
09.50-10.45	<b>State of The Art Lectures THIRST</b> <i>Chairs: Pierre-Yves Martin, Geneva; Daniel Hayoz, Fribourg</i>  Daniel G. Bichet, Montreal (CA)	<b>Room A</b>
10.45-11.15	Coffee break – Visit of the exhibition – Poster viewing	Exhibition space
11.15-12.15	<b>Oral Parallel Presentations</b>	
11.15-12.15	<b>Basic Science / Genetics / Experimental Nephrology</b> <i>Chairs: Olivier Bonny, Lausanne; Nilufar Mohebbi, Zurich</i> 6 oral presentations	<b>Room A</b>
11.15-12.15	<b>Transplantation</b> <i>Chairs: Patrizia Amico, Basel; Jean Villard, Geneva</i> 6 oral presentations	<b>Room B</b>
12.15-12.30	Short break	

# Oral communications

## Oral Parallel Presentations

11.15-12.15	<b>Basic Science / Genetics / Experimental Nephrology</b> <i>Chairs: Olivier Bonny, Lausanne; Nilufar Mohebbi, Zurich</i>	<b>Room A</b>
OC 07	<b>The deubiquitinase OTUB1 in kidney injury and fibrosis (NCCRproject)</b> Ms. Julia Günter <sup>1</sup> , Ms. Amalia Ruiz-serrano <sup>1</sup> , Dr. Svende Pfundstein <sup>1</sup> , Prof. Roland Wenger <sup>1</sup> , <b>Dr. Cwarsten Scholz</b> <sup>1</sup> <sup>1</sup> University of Zurich	
OC 08	<b>Low <math>\beta</math>-catenin expression levels during development alter renal morphology and function (NCCR Project)</b> <b>Dr. Stefan Rudloff</b> <sup>1</sup> , Dr. Delphine Lambert <sup>1</sup> , Ms. Andrea Karolin <sup>1</sup> , Ms. Andrea Bileck <sup>1</sup> , Prof. Uyen Huynh-Do <sup>1</sup> <sup>1</sup> University Hospital Bern	
OC 09	<b>Protein phosphatase 1 inhibitor 1 mediates cAMP-dependent stimulation of the renal NaCl cotransporter</b> <b>Dr. David Penton Ribas</b> <sup>1</sup> , Ms. Sandra Moser <sup>1</sup> , Ms. Agnieszka Wengi <sup>1</sup> , Dr. Jan Czogalla <sup>1</sup> , Dr. Lena Lindtoft Ronsenbaek <sup>2</sup> , Dr. Nourdine Faresse <sup>1</sup> , Prof. Robert Fenton <sup>2</sup> , Dr. Dominique Loffing <sup>1</sup> , Prof. Johannes Loffing <sup>1</sup> <sup>1</sup> University of Zurich, <sup>2</sup> University of Aarhus, Aarhus, Denmark	
OC 10	<b>Localization and role of uromodulin in the distal convoluted tubule</b> <b>Dr. Natsuko Tokonami</b> <sup>1</sup> , Dr. Tomoaki Takata <sup>1</sup> , Mr. Jan Beyeler <sup>1</sup> , Prof. Johannes Loffing <sup>1</sup> , Prof. Olivier Devuyst <sup>1</sup> , Dr. Eric Olinger <sup>1</sup> <sup>1</sup> University of Zurich	
OC 11	<b>Sex-hormone regulation of uric acid homeostasis</b> <b>Dr. Muriel Auberson</b> <sup>1</sup> , Ms. Fanny Durussel <sup>1</sup> , Prof. Olivier Bonny <sup>2</sup> <sup>1</sup> University of Lausanne, <sup>2</sup> University Hospital (CHUV) and University of Lausanne	
OC 12	<b>Absence of HIF pathway activation during chronic kidney disease (CKD): a pathway to anemia (NCCR project)</b> <b>Mr. Romain Dissard</b> <sup>1</sup> , Ms. Frederique Ino <sup>1</sup> , Ms. Vasiliki Delitsikou <sup>1</sup> , Prof. Sophie De Seigneux <sup>2</sup> <sup>1</sup> University of Geneva, <sup>2</sup> University Hospital Geneva	

## Oral communications

### Oral Parallel Presentations

11.15-12.15

#### Transplantation

*Chairs: Patrizia Amico, Basel; Jean Villard, Geneva*

Room B

OC 19

#### Clinical long-term outcomes of kidney transplantation from pediatric donors

**Dr. Yvonne Holzmann**<sup>1</sup>, Dr. Argyrios Georgalis<sup>1</sup>, Dr. Caroline Wehmeier<sup>1</sup>, Dr. Patricia Hirt-Minkowski<sup>1</sup>, Mr. Gideon Hönger<sup>1</sup>, Dr. Helmut Hopfer<sup>1</sup>, Prof. Lorenz Gürke<sup>1</sup>, Prof. Jürg Steiger<sup>1</sup>, Prof. Stefan Schaub<sup>1</sup>, Dr. Patrizia Amico<sup>1</sup>

<sup>1</sup>University Hospital Basel

OC 20

#### Aryl hydrocarbon receptor expression by macrophages and lymphocytes within infiltrates in BK Polyomavirus associated nephropathy

**Dr. Yassine Bouatou**<sup>1</sup>, Dr. Geurt Stokman<sup>2</sup>, Dr. Nike Claessen<sup>2</sup>, Dr. Joris Roelofs<sup>2</sup>, Prof. Frederike Bemelman<sup>2</sup>, Dr. Jesper Kers<sup>2</sup>, Prof. Sandrine Florquin<sup>2</sup>

<sup>1</sup>AMC/Geneva University Hospitals, Geneva, <sup>2</sup>AMC, Amsterdam, Netherlands

OC 21

#### Adherence and tolerability of prolonged-release tacrolimus in stable kidney and liver transplant patients after conversion from immediate-release tacrolimus in routine clinical practice: the IMPROVE study

**Dr. Marco Bonani**<sup>1</sup>, Dr. Alexandre Balaphas<sup>2</sup>, Dr. Giulia Bedino<sup>3</sup>, Prof. Léo Bühler<sup>2</sup>, Dr. Philipp Dutkowski<sup>1</sup>, Dr. Kathrin Fausch<sup>4</sup>, Dr. Silvia Gluderer<sup>5</sup>, Dr. Nicole Graf<sup>6</sup>, Dr. Patricia Hirt-Minkowski<sup>7</sup>, Prof. Beat Müllhaupt<sup>1</sup>, Dr. Carlo Schönholzer<sup>3</sup>, Dr. Martin Schulz<sup>5</sup>, Dr. Reto Venzin<sup>4</sup>, Prof. Rudolf P. Wüthrich<sup>1</sup>

<sup>1</sup>University Hospital Zurich, <sup>2</sup>University Hospital Geneva, <sup>3</sup>Lugano Regional Hospital, Lugano, <sup>4</sup>Cantonal Hospital Graubünden, Chur, <sup>5</sup>Astellas Pharma AG, Wallisellen, <sup>6</sup>Graf Biostatistics, Winterthur, <sup>7</sup>University Hospital Basel

## Oral communications

OC 22

#### Long-term outcomes after BK Polyomavirus replication in renal allograft recipients

**Ms. Nicole Bischof**<sup>1</sup>, Prof. Hans Hirsch<sup>1</sup>, Dr. Caroline Wehmeier<sup>1</sup>, Dr. Patrizia Amico<sup>1</sup>, Prof. Michael Dickenmann<sup>1</sup>, Dr. Patricia Hirt-Minkowski<sup>1</sup>, Prof. Jürg Steiger<sup>1</sup>, Dr. Thomas Menter<sup>1</sup>, Dr. Helmut Hopfer<sup>1</sup>, Prof. Stefan Schaub<sup>1</sup>

<sup>1</sup>University Hospital Basel

OC 23

#### Immunosuppressive drugs used to treat acute antibody-mediated rejection in kidney transplant recipients of the Swiss Transplant Cohort Study (STCS)

**Dr. Nancy Perrottet Ries**<sup>1</sup>, Dr. Dela Golshayan<sup>2</sup>, Dr. Samuel Rotman<sup>1</sup>, Dr. Solange Moll<sup>3</sup>, Dr. Helmut Hopfer<sup>4</sup>, Mrs. Emmanuelle Catana<sup>1</sup>, Dr. Michael Koller<sup>4</sup>, Dr. Jean-pierre Venetz<sup>2</sup>, Dr. Vincent Aubert<sup>1</sup>, Dr. Oriol Manuel<sup>2</sup>, Prof. Léo Bühler<sup>5</sup>, Dr. Karine Hadaya<sup>6</sup>, Prof. Thomas Mueller<sup>7</sup>, Prof. Uyen Huynh-Do<sup>8</sup>, Dr. Isabelle Binet<sup>9</sup>, Prof. Michael Dickenmann<sup>4</sup>, Prof. Jürg Steiger<sup>4</sup>, Prof. Manuel Pascual<sup>2</sup>

<sup>1</sup>University Hospital (CHUV), Lausanne, <sup>2</sup>University Hospital (CHUV) and University of Lausanne, <sup>3</sup>Geneva University Hospital and Medical School, Geneva, <sup>4</sup>University Hospital Basel, <sup>5</sup>Geneva University Hospitals and Medical School, Geneva, <sup>6</sup>Geneva University Hospitals, Geneva, <sup>7</sup>Universitätsspital Zürich, <sup>8</sup>Inselspital Bern, <sup>9</sup>Cantonal Hospital St Gallen

OC 24

#### Review of studies on changes in renal physiology induced by nephrectomy in living donors (NCCR project)

**Dr. Andreja Figurek**<sup>1</sup>, Prof. Valerie Luyckx<sup>1</sup>, Dr. Seraina Von Moos<sup>1</sup>, Prof. Thomas Mueller<sup>1</sup>

<sup>1</sup>University Spital Zürich



**AMGEN**<sup>®</sup>

invites you to a Scientific Lunch Symposium

## Innovation with impact: Calcimimetics for secondary HPT

**Lunch will be provided**

Thursday 7 December 2017  
 12:30 – 13:15

**Chair**

Prof. Dr. med. Michel Burnier  
 CHUV Lausanne, Switzerland

**Speakers**

Prof. Dr. med. Sophie De Seigneux  
 Hôpitaux Universitaires Genève, Switzerland

**Past, present and future: the continuing challenge of  
 CKD-MBD to reach targets in secondary HPT**

Prof. Dr. med. Andreas Bock  
 Kantonsspital Aarau, Switzerland  
**Etelcalcetide – What does the  
 clinical study data show?**

**AMGEN**<sup>®</sup>

AMGEN Switzerland AG, Dammstrasse 21, 6301 Zug, www.amgen.ch

SC-CH-CP-00039

## Thursday, December 7

12.30-13.15	<b>Satellite Lunch Symposium</b> Sponsored by <b>AMGEN</b> <i>Chair: Michel Burnier, Lausanne</i>	 <b>Room A</b>
	<b>Past, present and future: the continuing challenge of CKD-MBD to reach targets in secondary HPT</b> Sophie de Seigneux, Geneva <b>Etelcalcetide – What does the clinical study data show?</b> Andreas Bock, Aarau	
13.15-14.00	Standing lunch at the exhibition – Poster viewing	Exhibition space
14.00-15.00	<b>Parallel Symposia</b> 14.00-15.00 <b>Novel insight about complement dysregulation and diagnostic challenges</b> Sponsored lecture by <b>ALEXION</b> <i>Chairs: Karine Hadaya, Geneva; Andreas Kistler, Frauenfeld</i> Daniel Ricklin, Basel; Sacha Zeerleder, Amsterdam (NL)	 <b>Room A</b>
14.00-15.00	<b>Symposium NCCR Kidney.CH</b> <i>Chairs: Johannes Loffing, Zürich; Carsten Wagner, Zürich</i>	<b>Room B</b>
14.00-14.20	<b>The deubiquitinase OTUB1 in kidney injury and fibrosis</b> Carsten Scholz, Zürich	
14.20-14.40	<b>Long non-coding RNAs mediate regeneration of acute kidney injury</b> Johan Lorenzen, Zürich	
14.40-15.00	<b>Computers &amp; physiology – Modeling renal &amp; cardiac function</b> Diane de Zélicourt, Zürich	
15.00-15.30	Coffee break – Visit of the exhibition – Poster viewing	Exhibition space



GET CONNECTED TO...



...PATIENTS ON HOME DIALYSIS

## Thursday, December 7

15.30-16.15

Parallel Satellite Symposium

Sponsored by BAXTER

**Baxter**

**Room A**

**PD - Start Strong & Stay Strong**

*Chair: Valérie Jotterand Drepper, Geneva, CH*

15.30-15.50

**Improving PD Outcomes**

Mark Lambie, Stokes (GB)

15.50-16.10

**Impact of Remote Patient Management (RPM) in PD**

Rizwan Hamer, Coventry (UK)

16.10-16.15

**Discussions**

15.30-16.15

Parallel Satellite Symposium

Sponsored by OTSUKA

**Otsuka**

**Room B**

**Welcome & Introduction**

Michel Burnier, Lausanne

**Insights into the clinical evidence for Tolvaptan and on imaging in ADPKD**

Andreas Kistler, Frauenfeld

**Insights from the real world setting**

Daniel Fuster, Bern

**Q&A session moderated by**

Michel Burnier, Lausanne

16.15-16.30

Short break

**Parallel Satellite Symposium: Thursday, December 7 2017; 15.30 – 16.15 (Room A)**

### PD – START STRONG & STAY STRONG

Chair: Valérie Jotterand Drepper, Geneva

Speakers:

Improving PD Outcomes – **Mark Lambie**, Stokes (UK)

Impact of Remote Patient Management (RPM) in PD – **Rizwan Hamer**, Coventry (UK)

**Sponsored lecture: Friday, December 8 2017; 11.30 – 12:15 (Room A)**

### HOME DIALYSIS: SITUATION IN EUROPE

Chairs: Dominik Uehlinger, Bern and Andreas Bock, Aarau

Speaker: **Eric Goffin**, Bruxelles (BE)

**Baxter**

Baxter AG, Thurgauerstr. 130, 8152 Glattpark (Opfikon)



# Endlich! Licht in Sicht bei ADPKD.

JINARC® – Die erste krankheitsmodifizierende Therapie für Patienten mit autosomal-dominanter polyzystischer Nierenerkrankung (ADPKD)\* 1,2

- reduziert die Zunahme des Nierenvolumens<sup>1</sup>
- verlangsamt die Abnahme der renalen Funktion<sup>1</sup>
- mindert das Risiko von ADPKD-assoziierten Schmerzen<sup>1</sup>



\* Ausführliche Informationen zur Kasenzulassung entnehmen Sie bitte der Spezialistenliste unter [www.spezialistenliste.ch](http://www.spezialistenliste.ch)  
 \* Erwachsene mit chronischer Nierenerkrankung (CKD) im Stadium 1 bis 3 zu Behandlungsbeginn mit Anzeichen für rasch fortschreitende Erkrankung<sup>2</sup>

Referenzen:  
 1. Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2012; 367: 2407–2416.  
 2. Fachinformation Jinarc®: [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch)

**JINARC® (Tolvaptan) Kurzfachinformation.** Indikation: Verlangsamung der Progression von Zystenentwicklung und Nierenineffizienz bei autosomal-dominanter polyzystischer Nierenerkrankung (ADPKD) bei Erwachsenen mit chronischer Nierenerkrankung (CKD) (Stad. 1 - 3 zu Behandlungsbeginn) mit Anzeichen für rasch fortschreitende Erkrankung. **Dosierung:** 2 x täglich als geteilte Dosis von 45 mg + 15 mg (Anfangsdosis), Dosisstabilisation auf 60 mg + 30 mg oder 90 mg + 30 mg. Die Patienten müssen die höchste verträgliche Dosis Tolvaptan erhalten. Die Tolvaptan-Therapie darf nur von Ärzten eingeleitet und beaufsichtigt werden, die Erfahrung in der Behandlung von ADPKD haben und denen die Risiken einer Tolvaptan-Behandlung einschließlich der Hepatotoxizität sowie die notwendigen Überwachungsmaßnahmen vollumfänglich bekannt sind. **Kontraindikation:** Überempfindlichkeit gegen den Wirkstoff oder sonstige Bestandteile, erhöhte Leberenzyme u./o. Anzeichen oder Symptome einer Leberschädigung vor der Einleitung der Behandlung, die die Anforderungen für ein dauerhaftes Absetzen von Tolvaptan erfüllen; Volumendepletion; Hypermatriämie; Patienten, die Durst nicht wahrnehmen, oder auf Durst nicht reagieren können; Schwangerschaft; Stillzeit. **Warnhinweise und Vorsichtsmaßnahmen:** Tolvaptan wurde mit idiosyncratischen Zunahmen der Alanin- und Aspartat-Aminotransferase (ALT und AST) Spiegel und in seltenen Fällen mit einer gleichzeitigen Erhöhung des Gesamtbilirubins (BT) in Verbindung gebracht. Um das Risiko von erheblichen und/oder irreversiblen Leberschäden zu verringern, sind Bluttests zur Bestimmung der Lebertransaminasen und des Bilirubins vor Beginn der Behandlung mit Jinarc, danach monatlich für 18 Monate und danach regelmäßig alle 3 Monate erforderlich. Die gleichzeitige Überwachung auf Symptome, die auf Leberschäden hinweisen können (wie Müdigkeit, Appetitlosigkeit, Übelkeit, Beschwerden im rechten Oberbauch, Erbrechen, Fieber, Hautausschlag, Juckreiz, dunkler Urin oder Gelbsucht), wird empfohlen. Dehydrierung, Harnausflussobstruktion, Flüssigkeits- und Elektrolythaushalt, abnormale Serumnatriumspiegel, Anaphylaxie, Diabetes mellitus, erhöhte Hämoglobine, CYP3A- und P-gp-Induktoren. **Interaktionen:** Mäßige oder starke CYP3A-Inhibitoren; starke CYP3A- und P-gp-Induktoren; CYP3A-, CYP2C9-, P-gp- und Transporter-Substrate; Diuretika oder nicht diuretische Antihypertensiva; Vasopressin-Analoga. **Unerwünschte Wirkungen:** sehr häufig: Polydipsie, Kopfschmerzen, Schwindel, Durchfall, Mundtrockenheit, Nykturie, Pollakisurie, Polyurie, Müdigkeit, Durst; häufig: Dehydratation, Hypermatriämie, vermindelter Appetit, Hyperurikämie, Hyperglykämie, Schlaflosigkeit, Herzklopfen, Dyspnoe, Blähungen, Verstopfung, Dyspepsie, gastroösophageale Refluxkrankheit, gestörte Leberfunktion, Exanthem, Juckreiz, Muskelkrämpfe, Asthenie, erhöhte Alanin-Aminotransferase, erhöhte Aspartat-Aminotransferase, Gewichtsabnahme. **Packungen:** 28 Tabletten: 15, 30 mg Tolvaptan. 56 Tabletten: 28 x 45 mg + 28 x 15 mg Tolvaptan. 56 Tabletten: 28 x 60 mg + 28 x 30 mg Tolvaptan. 56 Tabletten: 28 x 90 mg + 28 x 30 mg Tolvaptan. Konsultieren Sie bitte vor einer Verschreibung die vollständige Fachinformation, die auf der Homepage von Swissmedic unter [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch) publiziert ist. **Abgabekategorie:** A, **Zulassungsinhaber:** Otsuka Pharmaceutical (Switzerland) GmbH, Sägereistrasse 20, 8152 Glattbrugg, Stand: Februar 2016 (v001).

## Thursday, December 7

16.30-17.30	<b>Parallel Symposia</b>	
16.30-17.30	<b>Nephropathology</b> <i>Chairs: Solange Moll, Geneva; Helmut Hopfer, Basel</i>	<b>Room A</b>
16.30-16.45	<b>Lupus nephritis: what's new about histopathological scoring?</b> Ariana Gaspert, Zürich	
16.45-17.00	<b>IgA GN: what's new about histopathological Oxford classification?</b> Vera Genitsch-Gratwohl, Bern	
17.00-17.15	<b>Banff classification: an update</b> Samuel Rotman, Lausanne	
17.15-17.30	<b>Biopsy findings in patients after stem cell transplantation</b> Thomas Menter, Basel	
16.30-17.40	<b>Symposium WGIKD</b> <i>Chairs: Olivier Devuyst, Zürich; Uyen Huynh-Do, Bern</i>	<b>Room B</b>
16.30-16.50	<b>Basic sciences lysosomes and PT function</b> Olivier Devuyst, Zürich	
16.50-17.10	<b>Case presentation Cystinosis</b> Sibylle Tschumi, Bern	
17.10-17.40	<b>Fabry Diseases - Inherited Kidney Diseases</b> Sponsored lecture by <b>SHIRE</b> Christine Kurschat, Koeln (DE)	

17.45-18.30	<b>Poster walk</b>	<b>Poster Area</b>
Topics	– <b>Clinical Nephrology / Hypertension / Mineral / Electrolytes</b>	
Jury	Sophie de Seigneux, Geneva; Belen Ponte, Geneva	
Topics	– <b>Basic science / Genetics / Experimental Nephrology</b>	
Jury	Eric Féraille, Geneva; Nilufar Mohebbi, Zürich	
Topics	– <b>Hemodialysis (HD) / Peritoneal Dialysis (PD)</b>	
Jury	Thomas Hernandez, Geneva; Menno Pruijm, Lausanne	
Topic	– <b>Transplantation</b>	
Jury	Karine Hadaya, Geneva; Thomas Müller, Zürich	

19.45 **WELCOME DRINK & CONGRESS DINNER** **Room A**  
**Poster Prize Awards**



# Thursday, December 7

Room A

## CONGRESS DINNER

19.45 **WELCOME DRINK & CONGRESS DINNER**  
Poster Prize Awards



The Forum Fribourg will provide a perfect setting for the Congress Dinner of the Swiss Society of Nephrology. Enjoy a unique atmosphere, combined with first-class service and excellent cuisine.

We await your reservation with pleasure when registering online on [www.meeting-com.ch](http://www.meeting-com.ch). Pre-reservation is highly recommended. Additional tickets will be available at the registration desk on a first come first served basis.

**Price: CHF 90.00/ticket**

**Forum Fribourg – Route du Lac 12, 1763 Granges-Paccot**

# Friday, December 8

## Swiss Society of Nephrology Congress

### Special Satellite Symposium: Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia

Sprache: französisch  
Slides und Fragen: auch auf deutsch und italienisch

From 07.00 Registration

07.45-09.15 **GENERAL ASSEMBLY SGN-SSN**

09.15-09.45 **The Swiss Dialysis Registry**  
Patrice Ambühl, Zürich  
*Chair: Pierre-Yves Martin, Geneva*

09.45-10.00 **SGN-SSN Publication Award 2017**  
*Chair: Pierre-Yves Martin, Geneva*  
Presentation and short address  
Olivier Bonny, CHUV, Lausanne  
**Renal Fanconi Syndrome and Hypophosphatemic Rickets in the Absence of Xenotropic and Polytopic Retroviral Receptor in the Nephron**



09.30-11.00 **Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia**

**Health literacy and shared decision making: Room 3E**  
– un programme d'éducation thérapeutique en néphrologie  
– Programm für therapeutische Patientenschulung in der Nephrologie  
– un programma di formazione terapeutica in nefrologia  
Pascale Lefuel, Infirmière spécialiste clinique en néphrologie, Geneva ;  
Anne Dufey-Teso, Néphrologue, Geneva

10.00-10.15 Short break

Room A

Room A

Room A

# Hyperkalemia Management in Cardio-renal Patients

SGN/SSN Congress – Forum Fribourg, Room A  
Friday, December 8<sup>th</sup>, 2017, 10.15 – 11.00 h

## Part I: Hyperkalemia – A Silent Killer?

PD Dr med. Andreas Kistler  
(Spital Thurgau, Frauenfeld)

## Part II: Agent in Double Mission – Treatment of Hyperkalemia and Optimization of RAAS Inhibitor Therapy

Dr med. Albin Schwarz (Stadtspital Waid, Zürich)



### Meet the expert

Dr med. Albin Schwarz, Time: 13.15 h,  
Vifor booth Interactive Q&A session

Simply scan  
to add to  
your agenda



## Friday, December 8

10.15-11.00	Satellite Symposium Sponsored by VIFOR		<b>Room A</b>
10.15-10.35	<b>Hyperkalemia Management in Cardio-Renal Patients</b> <b>Hyperkalemia – A Silent Killer?</b> Andreas Kistler, Frauenfeld		
10.35-11.00	<b>Agent in Double Mission – Treatment of Hyperkalemia and Optimization of RAAS Inhibitor Therapy</b> Albin Schwarz, Zürich		
11.00-11.30	Coffee break – Visit of the exhibition – Poster viewing		Exhibition space
11.30-12.15	<b>Home dialysis: situation in Europe</b> Sponsored lecture by BAXTER		<b>Room A</b>
	<i>Chairs: Dominik Uehlinger, Bern; Andreas Bock, Aarau</i>		
	Eric Goffin, Bruxelles (BE)		
11.30-12.15	<b>Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia</b>		<b>Room 3E</b>
	<b>Comment adapter la prise en soins du patient à ses motivations ? Où le patient va-t-il vous amener ? Wie lässt sich die Betreuung des Patienten an seine Motivation anpassen ? Wohin führt Sie der Patient ? Come conformare le cure al paziente con le sue motivazioni ? Dove ci porterà il paziente ?</b>		
	Christiane Helary, Infirmière spécialiste clinique en diabétologie et formatrice en éducation thérapeutique, Geneva		
12.15-12.30	Short break		

# Facing the Remaining Challenges for Better Long-Term Outcomes After Kidney Transplantation

Friday, 8 December 2017, 12.30–13.15 h

**Astellas Satellite Symposium at the SGN-SSN Annual Meeting 2017**  
49<sup>th</sup> Annual Meeting of the Swiss Society of Nephrology, 7–8 December 2017, Fribourg, Switzerland

12.30h–12.35h: **Welcome**

**PD Dr. Patrizia Amico**, University Hospital Basel  
**Prof. Dr. Manuel Pascual**, Centre Hospitalier Universitaire Vaudois

12.35h–12.50h: **How can we address medication non-adherence in our kidney transplant patients?**

**Prof. Dr. Dirk Kuypers**, University Hospital Leuven, Leuven, Belgium

12.50h–13.05h: **Can we COMMIT to improve long-term outcomes in kidney transplantation?**

**Prof. Dr. Daniel Serón**, University Hospital Vall d'Hebron, Barcelona, Spain

13.05h–13.15h: **Panel Discussion**

13.15h: **Conclusions & Close**

**PD Dr. Patrizia Amico & Prof. Dr. Manuel Pascual**

APCHADVLB1017e

**Friday, December 8**

12.30-13.15

**Satellite Symposium**  
Sponsored by **ASTELLAS**



**Room A**

**Facing the Remaining Challenges for Better Long-Term Outcomes After Kidney Transplantation**

12.30-12.35

**Welcome**

Patrizia Amico, Basel ; Manuel Pascual, Lausanne

12.35-12.50

**How can we address medication non-adherence in our kidney transplant patients?**

Dirk Kuypers, Leuven (B)

12.50-13.05

**Can we COMMIT to improve long-term outcomes in kidney transplantation?**

Daniel Serón, Barcelona (E)

13.05-13.15

**Panel Discussion**

13.15

**Conclusions & Close**

Patrizia Amico, Basel ; Manuel Pascual, Lausanne

12.30-13.15

**Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia**

**Room 3E**

**Multidisciplinarité dans la prise en charge de la néphropathie diabétique et rôle infirmier**

**Multidisziplinarität bei der Behandlung der diabetischen Nephropathie und Rolle der Pflege**

**Pluridisciplinarità nella presa in carico della nefropatia diabetica e ruolo dell'infermiere**

Dina Nobre, Infirmière de recherche pour le programme cantonal rein/diabète au CHUV, Lausanne ; Nancy Helou, Professeure HES associée, HESAV, Lausanne

13.15-14.00

Standing lunch at the exhibition – Poster viewing

Exhibition space



## Friday, December 8

14.00-15.00	Oral Parallel Presentations	
14.00-15.00	<b>Clinical Nephrology / Hypertension / Mineral / Electrolytes</b> <b>Room A</b> <i>Chairs: Spyridon Arampatzis, Bern; Grégoire Würzner, Lausanne</i> 6 oral presentations	
14.00-15.00	Hemodialysis (HD) / Peritoneal Dialysis (PD) <b>Room B</b> <i>Chairs: Luca Gabutti, Locarno; Fabien Stucker, Neuchâtel</i> 6 oral presentations	
15.00-15.30	Coffee break – Visit of the exhibition	Exhibition space

## Oral communications

14.00-15.00	<b>Clinical Nephrology / Hypertension / Mineral / Electrolytes</b> <b>Room A</b> <i>Chairs: Spyridon Arampatzis, Bern; Grégoire Würzner, Lausanne</i>
OC 1	<b>Reduced cortical oxygenation predicts progressive renal function decline in humans: results of a prospective study</b> <b>Dr. Menno Pruijm</b> <sup>1</sup> , Mr. Bastien Milani <sup>1</sup> , Dr. Edward Pivin <sup>1</sup> , Prof. Matthias Stuber <sup>1</sup> , Prof. Bruno Vogt <sup>2</sup> , Prof. Michel Burnier <sup>1</sup> <sup>1</sup> CHUV Lausanne, <sup>2</sup> Inselspital, Bern
OC 2	<b>An MRI based score for assessment of fibrosis in CKD patients</b> <b>Dr. Lena Berchtold</b> <sup>1</sup> , Dr. Iris Friedli <sup>2</sup> , Dr. Lindsey Crowe <sup>2</sup> , Dr. Solange Moll <sup>3</sup> , Dr. Karine Hadaya <sup>2</sup> , Dr. Thomas De Perrot <sup>2</sup> , Prof. Pierre-Yves Martin <sup>4</sup> , Prof. Jean-paul Vallée <sup>2</sup> , Prof. Sophie De Seigneux <sup>1</sup> <sup>1</sup> University Hospital Geneva, <sup>2</sup> Geneva University Hospitals, <sup>3</sup> Geneva University Hospital and Medical School, <sup>4</sup> AMC/Geneva University Hospitals
OC 3	<b>Prevalences of distal renal tubular acidosis and other metabolic abnormalities among 534 non-selected kidney stone formers – a single center study</b> <b>Prof. Bernhard Hess</b> <sup>1</sup> , Dr. Jerzy Sromicki <sup>2</sup> <sup>1</sup> KidneyStone Center Zurich, Klinik Im Park, Zurich, <sup>2</sup> University Hospital, Zurich
OC 4	<b>Dietary sodium intake modulates urinary potassium excretion in humans</b> <b>Prof. Antoinette Pechere</b> <sup>1</sup> , Dr. Khalil Udwan <sup>2</sup> , Ms. Marinette Chiki <sup>1</sup> , Dr. Lena Berchtold <sup>1</sup> , Prof. Sophie De Seigneux <sup>1</sup> , Prof. Pierre-Yves Martin <sup>3</sup> , Prof. Reto Krapf <sup>4</sup> , Prof. Johannes Loffing <sup>5</sup> , Prof. Eric Feraille <sup>2</sup> <sup>1</sup> University Hospital Geneva, <sup>2</sup> University of Geneva, <sup>3</sup> AMC/Geneva University Hospitals, <sup>4</sup> University of Basel, <sup>5</sup> University of Zurich
OC 5	<b>Phenotype of kidney stone formers with renal phosphate leak</b> <b>Dr. Nasser Dhayat</b> <sup>1</sup> , Mr. David Lüthi <sup>1</sup> , Ms. Lisa Schneider <sup>1</sup> , Mr. Cedric Mattmann <sup>1</sup> , Prof. Bruno Vogt <sup>1</sup> , Prof. Daniel Fuster <sup>2</sup> <sup>1</sup> University of Bern, <sup>2</sup> University of Bern, Swiss National Centre of Competence in Research (NCCR) TransCure, Bern
OC 6	<b>Prediction of kidney function after nephrectomy in donor and recipient</b> <b>Ms. Laura Hapuoja</b> <sup>1</sup> , Dr. Kerstin Huebel <sup>2</sup> , Dr. Olivier De Rougemont <sup>2</sup> , Prof. Thomas Mueller <sup>2</sup> <sup>1</sup> University of Zurich, <sup>2</sup> University Hospital Zurich

## Oral communications

- 14.00-15.00**    **Hemodialysis (HD)/Peritoneal Dialysis (PD)**    **Room B**  
*Chairs: Luca Gabutti, Locarno; Fabien Stucker, Neuchâtel*
- OC 13**    **Implementation of remote patient management in the care of automated peritoneal dialysis patients in Switzerland: 18 months experience**  
**Dr. Valérie Jotterand Drepper**<sup>1</sup>, Prof. Pierre-Yves Martin<sup>1</sup>, Dr. Thomas Hernandez<sup>1</sup>, Dr. Catherine Stoermann-Chopard<sup>1</sup>  
<sup>1</sup>AMC/Geneva University Hospitals
- OC 14**    **Experience with rivaroxaban treatment in 10 haemodialysis patients**  
**Mr. Davide Spica**<sup>1</sup>, Dr. Beatrice Paul<sup>1</sup>, Prof. Stephan Segerer<sup>1</sup>, Prof. Andreas Bock<sup>1</sup>  
<sup>1</sup>Kantonsspital Aarau
- OC 15**    **Do measurements of serum ferritin and TSAT as performed in clinical practice accurately guide iv iron therapy with ferrum carboxymaltose in hemodialysis-patients?**  
**Mr. Matthias Diebold**<sup>1</sup>, Dr. Andreas Kistler<sup>1</sup>  
<sup>1</sup>Kantonsspital Frauenfeld
- OC 16**    **The role of ISO-9001:2008 certification for management and quality control in dialysis: the experience of a Swiss centre**  
**Dr. Claudia Ferrier**<sup>1</sup>, Prof. Stefano Calciolari<sup>2</sup>, Prof. Mario Bianchetti<sup>3</sup>  
<sup>1</sup>Nefrocentro Clinica Luganese, NetMEGS, Università della Svizzera Italiana, Lugano, <sup>2</sup>Istituto IdEP, Facoltà di Scienze Economiche, Università della Svizzera Italiana, Lugano, <sup>3</sup>Facoltà di Biomedicina, Università della Svizzera Italiana, Lugano
- OC 17**    **Risk factors for community-acquired Acute Kidney Injury in patients with and without chronic kidney injury and impact of its initial management on prognosis: a prospective observational study**  
**Dr. Patrick Saudan**<sup>1</sup>, Dr. Fabien Stucker<sup>2</sup>, Dr. Belen Ponte<sup>1</sup>, Dr. Cyrielle Alves<sup>1</sup>, Prof. Thomas Perneger<sup>1</sup>, Prof. Pierre-Yves Martin<sup>1</sup>  
<sup>1</sup>Hôpitaux universitaires de Geneva, <sup>2</sup>Hôpital de la Providence, Neuchâtel,

## Oral communications

- OC 18**    **Toward a better understanding of chronic kidney disease using metabolomics**  
Mr. Yoric Gagnebin<sup>1</sup>, Mr. Julian Pezzati<sup>1</sup>, Dr. Pierre Lescuyer<sup>2</sup>, Prof. Sophie De Seigneux<sup>3</sup>, Dr. Julien Broccard<sup>1</sup>, Prof. Serge Rudaz<sup>1</sup>, **Dr. Belen Ponte**<sup>3</sup>  
<sup>1</sup>University of Geneva and Lausanne, Geneva and Lausanne, <sup>2</sup>Geneva University Hospitals, Geneva, <sup>3</sup>Geneva University Hospitals and Medical School, Geneva, Switzerland



## Friday, December 8

15.30-16.30	<b>Hot Topics</b> <i>Chairs: Uyen Huynh-Do, Bern; Michael Dickenmann, Basel</i>	<b>Room A</b>
15.30-16.00	<b>Kidney paired donation – The Australian experience</b> Paolo Ferrari, Lugano (CH)/Sydney (AU)	
16.00-16.30	<b>Hypertension targets in CKD</b> Michel Burnier, Lausanne	
16.30	<b>Farewell</b> Pierre-Yves Martin, Geneva	

## Poster presentations

<b>P 1 – P 23</b>	<b>Clinical Nephrology / Hypertension / Mineral / Electrolytes</b>
<b>P 24 – P 39</b>	<b>Basic Science / Genetics / Experimental Nephrology</b>
<b>P 40 – P 46</b>	<b>Hemodialysis / Peritoneal Dialysis</b>
<b>P 47 – P 56</b>	<b>Transplantation</b>

### Clinical Nephrology / Hypertension / Mineral / Electrolytes

- P 1** **Impact of citrate supplementation on urinary risk profile in Swiss recurrent calcium stone formers (NCCR Project)**  
**Ms. Gioia Fischer<sup>1</sup>**, Ms. Anna Wiegand<sup>1</sup>, Dr. Harald Seeger<sup>1</sup>, Prof. Daniel Fuster<sup>2</sup>, Prof. Olivier Bonny<sup>3</sup>, Dr. Thomas Hernandez<sup>4</sup>, Dr. Min Jeong KIM<sup>5</sup>, Prof. Carsten Wagner<sup>6</sup>, Dr. Nilufar Mohebbi<sup>1</sup>  
<sup>1</sup>University Hospital Zurich, <sup>2</sup>University Hospital Bern, <sup>3</sup>CHUV Lausanne, <sup>4</sup>University Hospital Geneva, <sup>5</sup>University Hospital Basel, <sup>6</sup>University of Zurich
- P 2** **Zinc deficiency in chronic kidney disease is not related to increased urinary excretion**  
**Dr. Philippe Braconnier<sup>1</sup>**, Dr. Sébastien Lenglet<sup>1</sup>, Dr. Marc Augsburger<sup>1</sup>, Prof. Michel Burnier<sup>2</sup>, Prof. Aurélien Thomas<sup>3</sup>, Dr. Menno Pruijm<sup>1</sup>  
<sup>1</sup>University Hospital (CHUV), Lausanne, <sup>2</sup>CHUV Lausanne, <sup>3</sup>University of Lausanne
- P 3** **Essential trace elements in chronic kidney disease patients in Switzerland**  
**Dr. Philippe Braconnier<sup>1</sup>**, Dr. Sébastien Lenglet<sup>1</sup>, Dr. Marc Augsburger<sup>1</sup>, Prof. Michel Burnier<sup>2</sup>, Prof. Aurélien Thomas<sup>3</sup>, Dr. Menno Pruijm<sup>1</sup>  
<sup>1</sup>University Hospital (CHUV), Lausanne, <sup>2</sup>CHUV Lausanne, <sup>3</sup>University of Lausanne
- P 4** **Longitudinal follow-up of stone formers in Switzerland - NCCR Kidney.CH project**  
**Prof. Olivier Bonny<sup>1</sup>**, Prof. Daniel Fuster<sup>2</sup>, Dr. Nilufar Mohebbi<sup>3</sup>, Dr. Thomas Hernandez<sup>4</sup>, Dr. Min Jeong KIM<sup>5</sup>, Dr. Florian Buchkremer<sup>6</sup>, Dr. Beat Roth<sup>2</sup>, Dr. Grazia Cereghetti<sup>7</sup>, Prof. Carsten Wagner<sup>8</sup>  
<sup>1</sup>University Hospital (CHUV), Lausanne, <sup>2</sup>Inselspital Bern, <sup>3</sup>Universitätsspital Zürich, <sup>4</sup>Hôpitaux universitaires de Geneva, <sup>5</sup>University Hospital Basel, <sup>6</sup>Kantonsspital Aarau, <sup>7</sup>NCCR Kidney.CH, Zurich, <sup>8</sup>University of Zurich

## Poster presentations

- P 5**      **Pre-existing, Perioperative and Postoperative Chronic Kidney Disease in Patients Receiving Orthotopic Liver Transplantation**  
Mr. Fabian Hauenstein<sup>1</sup>, Dr. Guido Beldi<sup>1</sup>, Prof. Bruno Vogt<sup>1</sup>, Prof. Uyen Huynh-Do<sup>1</sup>, Dr. Vanessa Banz<sup>1</sup>, **Dr. Daniel Sidler<sup>1</sup>**  
<sup>1</sup>University Hospital Bern
- P 6**      **Change in V-ATPase B1 but not B2 subunit abundance in human urinary exosomes in response to acute acid/alkali loading and distal renal tubular acidosis**  
**Dr. Ganesh Pathare<sup>1</sup>**, Dr. Nasser Dhayat<sup>1</sup>, Dr. Nilufar Mohebbi<sup>2</sup>, Prof. Carsten Wagner<sup>3</sup>, Dr. Alexandru Bobulescu<sup>4</sup>, Prof. Orson Moe<sup>4</sup>, Prof. Daniel Fuster<sup>1</sup>  
<sup>1</sup>University of Bern, <sup>2</sup>University Hospital Zurich, <sup>3</sup>University of Zurich, <sup>4</sup>University of Texas Southwestern Medical Center, Dallas, Texas, USA
- P 7**      **Lipodystrophy increases the risk of developing chronic kidney disease in HIV- positive patients in Switzerland: the LIPOKID study**  
**Dr. Yassine Bouatou<sup>1</sup>**, Dr. Angèle Gayet-ageron<sup>1</sup>, Dr. Enos Bernasconi<sup>2</sup>, Prof. Manuel Battegay<sup>3</sup>, Dr. Matthias Hoffmann<sup>4</sup>, Dr. Cornelia Staehelin<sup>5</sup>, Dr. Laurent Merz<sup>6</sup>, Dr. Helen Kovari<sup>7</sup>, Dr. Christoph Fux<sup>8</sup>, Prof. Alexandra Calmy<sup>1</sup>, Prof. Sophie De Seigneux<sup>1</sup>  
<sup>1</sup>University Hospital Geneva, <sup>2</sup>Regional Hospital Lugano, Lugano, <sup>3</sup>University Hospital Basel, <sup>4</sup>Kantonsspital St. Gallen, <sup>5</sup>Bern University Hospital, <sup>6</sup>CHUV Lausanne, <sup>7</sup>University Hospital Zurich, <sup>8</sup>Kantonsspital Aarau
- P 8**      **Diagnostic accuracy of immunofluorescence versus immunoperoxidase staining to distinguish immune complex-mediated glomerulonephritis and C3 dominant glomerulopathy**  
**Dr. Yassine Bouatou<sup>1</sup>**, Dr. Jesper Kers<sup>2</sup>, Ms. Marie Chevalier Florquin<sup>2</sup>, Dr. Nike Claessen<sup>2</sup>, Dr. Tri N guyen<sup>3</sup>, Dr. Jeffrey Damman<sup>2</sup>, Dr. Henrique Proenca<sup>4</sup>, Dr. Joris Roelofs<sup>2</sup>, Prof. Sandrine Florquin<sup>2</sup>  
<sup>1</sup>AMC/Geneva University Hospitals, <sup>2</sup>AMC, Amsterdam, Netherlands, <sup>3</sup>UMCU, Utrecht, Netherlands, <sup>4</sup>Universidade Metropolitana de Santos (UNIMES), Santos, Brazil
- P 9**      **Medication adherence during work-up for Conn syndrome**  
**Dr. Jürgen Bohlender<sup>1</sup>**, Dr. Friederike Sandbaumhüter<sup>1</sup>, Prof. Bruno Vogt<sup>1</sup>, Prof. Manuel Haschke<sup>1</sup>  
<sup>1</sup>Inselspital, Bern University Hospital

## Poster presentations

- P 10**      **An algorithm to prevent overly rapid correction of hyponatremia by urine volume monitoring**  
**Dr. Florian Buchkremer<sup>1</sup>**, Prof. Stephan Segerer<sup>1</sup>, Prof. Andreas Bock<sup>1</sup>  
<sup>1</sup>Kantonsspital Aarau
- P 11**      **Renal Amyloidosis is not sufficiently prevented in patients with FMF in Armenia**  
**Dr. Sofi Sarinyan<sup>1</sup>**, Dr. Helen Nazaryan<sup>2</sup>, Dr. Armen Sanamyan<sup>2</sup>, Prof. Gayane Amaryan<sup>1</sup>, Prof. Ernst Leumann<sup>3</sup>, Prof. Ara Babloyan<sup>2</sup>, Prof. Ashot Sarkissian<sup>2</sup>  
<sup>1</sup>Yerevan State Medical University, Yerevan, Armenia, <sup>2</sup>Arabkir Medical Centre, Yerevan, Armenia, <sup>3</sup>University Children's Hospital, Zurich
- P 12**      **Microbiological analysis of hemodialysis water at the university teaching hospital of Yaounde, Cameroon**  
**Dr. Cedric Gueguim<sup>1</sup>**, Dr. Alain Ragon<sup>2</sup>, Prof. Francois Kaze<sup>1</sup>, Prof. Hortense Gonsu Kamga<sup>1</sup>  
<sup>1</sup>University of Yaounde I, Yaounde, Cameroon, <sup>2</sup>Hospital of Conception, Marseille, France
- P 13**      **NOSTONE Trial: Randomized double-blind placebo-controlled trial assessing the efficacy of standard and low dose hydrochlorothiazide treatment in the recurrence prevention of calcareous nephrolithiasis**  
Dr. Patrizia Amico<sup>1</sup>, Dr. Giulia Bedino<sup>2</sup>, Prof. Olivier Bonny<sup>3</sup>, Dr. Florian Buchkremer<sup>4</sup>, Dr. Rosaria Del Giorno<sup>5</sup>, Dr. Thomas Hernandez<sup>6</sup>, Dr. Nasser Dhayat<sup>7</sup>, Dr. Nicolas Faller<sup>7</sup>, Prof. Luca Gabutti<sup>5</sup>, Dr. Carina Hüsler<sup>8</sup>, Dr. Irene Koneth<sup>8</sup>, Dr. Michael Mayr<sup>1</sup>, Dr. Nilufar Mohebbi<sup>9</sup>, Dr. Urs Odermatt<sup>10</sup>, Dr. Lisa Pellegrini<sup>2</sup>, Dr. Beat Roth<sup>7</sup>, Dr. Harald Seeger<sup>9</sup>, Dr. Carlo Schönholzer<sup>2</sup>, Dr. Catherine Stoermann-Chopard<sup>6</sup>, **Dr. Luca Tamò<sup>11</sup>**, Prof. Daniel Teta<sup>12</sup>, Dr. Reto Venzin<sup>13</sup>, Prof. Daniel Fuster<sup>7</sup>  
<sup>1</sup>University Hospital Basel, <sup>2</sup>EOC, Lugano, <sup>3</sup>CHUV, Lausanne, <sup>4</sup>Kantonsspital Aarau, <sup>5</sup>EOC, Bellinzona, <sup>6</sup>University Hospital Geneva, <sup>7</sup>University Hospital Bern, <sup>8</sup>Kantonsspital St. Gallen, <sup>9</sup>University Hospital Zurich, <sup>10</sup>Kantonsspital Luzern, <sup>11</sup>University of Bern, <sup>12</sup>Hôpital Cantonal du Valais, Sion, <sup>13</sup>Kantonsspital Graubünden, Chur

## Poster presentations

- P 14**      **hypokalemic metabolic alkalosis, hypertension and diabetes – what is the link?**  
**Mr. Marius Vögelin**<sup>1</sup>, Dr. Richard Cathomas<sup>1</sup>, Dr. Niklaus Kamber<sup>1</sup>, Prof. Thomas Fehr<sup>1</sup>  
<sup>1</sup>Kantonsspital Graubünden, Chur
- P 15**      **Single center experience with tolvaptan in nine patients with autosomal dominant polycystic kidney disease (ADPKD)**  
**Dr. Nina Hess**<sup>1</sup>, Dr. Emily Pollock<sup>1</sup>, Dr. Verena Schärer<sup>1</sup>, Dr. Claudia Kobel<sup>1</sup>, Dr. Nina Weber<sup>1</sup>, Dr. Alexander Ritter<sup>1</sup>, Prof. Thomas Mueller<sup>1</sup>, Prof. Rudolf P. Wüthrich<sup>1</sup>, Prof. Johan Lorenzen<sup>1</sup>  
<sup>1</sup>University Hospital Zurich
- P 16**      **Could polymerase chain reaction (pcr) avert worsening acute kidney injury? a case of leptospirosis in a regional hospital**  
**Dr. James TATAW**<sup>1</sup>, Dr. Terezija Gracin<sup>1</sup>, Dr. Cecile Bassi<sup>1</sup>  
<sup>1</sup>Hôpital du Jura bernois SA, Moutier
- P 17**      **Vascular aging processes accelerate during the whole life following an alarming kinetic; Pulse Wave Velocity as an objective counterpart that time flies**  
**Prof. Luca Gabutti**<sup>1</sup>, Dr. Rosaria Del Giorno<sup>1</sup>  
<sup>1</sup>EOC, Bellinzona
- P 18**      **A rare renal complication leading to the first diagnosis of chronic pancreatitis**  
**Dr. Nikolaos Drivakos**<sup>1</sup>, Dr. Cédric Pulver<sup>1</sup>, Dr. Annette Marie Wons<sup>1</sup>, Dr. Jörg Neuweiler<sup>1</sup>, Dr. Françoise-Isabelle Binet<sup>1</sup>, Dr. Dimitrios Tsinalis<sup>1</sup>  
<sup>1</sup>Kantonsspital St. Gallen
- P 19**      **Excessive consumption of “over-the-counter” vitamin D supplements leading to severe hypercalcemia and acute kidney injury: case report**  
**Dr. Catherine Beglinger**<sup>1</sup>, Dr. Dimitrios Tsinalis<sup>2</sup>, Dr. Min Jeong KIM<sup>1</sup>, Mrs. Karin Jung<sup>1</sup>, Prof. Michael Brändle<sup>1</sup>, Dr. Françoise-Isabelle Binet<sup>2</sup>  
<sup>1</sup>Cantonal Hospital St. Gallen, <sup>2</sup>Kantonsspital St. Gallen

## Poster presentations

- P 20**      **mTOR Inhibitor: a new indication for a rare disease?**  
**Dr. Ann-Kathrin Schwarzkopf**<sup>1</sup>  
<sup>1</sup>Hirslanden Bern, Salem-Spital, Bern
- P 21**      **Diabetic muscle infarction: a diagnostic challenge for clinicians and radiologists**  
**Mrs. Jennifer Scotti Gerber**<sup>1</sup>, Dr. Davide Giunzioni<sup>1</sup>, Dr. Silvio Pianca<sup>1</sup>, Prof. Jos C Van Den Berg<sup>1</sup>, Dr. Carlo Schönholzer<sup>1</sup>  
<sup>1</sup>Regional Hospital Lugano
- P 22**      **Combined primary and secondary hyperparathyroidism in a liver transplant patient: a case report**  
**Dr. Curzio Solca**<sup>1</sup>, Dr. Benedetta Terziroli<sup>2</sup>, Dr. Fabio Cattaneo<sup>3</sup>, Dr. Claudia Ferrier<sup>1</sup>  
<sup>1</sup>Nefrocentro Clinica Luganese Moncucco, Lugano, <sup>2</sup>Epatocentro, Lugano, <sup>3</sup>Clinica Luganese Moncucco, Lugano
- P 23**      **Unexplained severe lactic acidosis in a non-diabetic chronic hemodialysis patient: do you consider to make a phone call to the pharmacy?**  
**Ms. Céline Aeberhard**<sup>1</sup>, Dr. Ould Maouloud Hemett<sup>1</sup>, Dr. Yvan Fleury<sup>1</sup>, Dr. Benoit Fellay<sup>1</sup>, Dr. Jean Luc Magnin<sup>1</sup>, Dr. Pierre Lescuyer<sup>2</sup>, Prof. Daniel Hayoz<sup>1</sup>, Dr. Eric Descombes<sup>1</sup>  
<sup>1</sup>HFR, Hôpital Cantonal Fribourg, <sup>2</sup>Geneva University Hospitals
- Basic Science/Genetics/Experimental Nephrology**
- P 24**      **Prevalence rates and risk factors for chronic kidney disease in sub-Saharan Africa: A pilot study in a semirural region of Tanzania**  
Dr. Michael Mayr<sup>1</sup>, **Mr. Nikolai Hodel**<sup>1</sup>  
<sup>1</sup>University Hospital Basel
- P 25**      **Lack of Fetuin-A exacerbates interstitial kidney fibrosis (NCCR project)**  
**Dr. Kevin Dessalle**<sup>1</sup>, Dr. Delphine Lambert<sup>1</sup>, Dr. Stefan Rudloff<sup>2</sup>, Prof. Uyen Huynh-Do<sup>3</sup>  
<sup>1</sup>Inselspital, Bern University Hospital, <sup>2</sup>University Hospital Bern, <sup>3</sup>Inselspital Bern

## Poster presentations

- P 26**      **Impact of Dietary Amino Acids on CKD Progression in Rats (NCCR project)**  
**Dr. Samyuktha Pillai<sup>1</sup>**, Dr. Giovanni Pellegrini<sup>1</sup>, Prof. François Verrey<sup>1</sup>  
<sup>1</sup>University of Zurich
- P 27**      **Podocyte damage is induced by aberrantly glycosylated anti-PLA2R-IgG4 via the lectin complement pathway in membranous nephropathy**  
**Dr. George Haddad<sup>1</sup>**  
<sup>1</sup>University of Zurich
- P 28**      **Young woman with bilateral renal hypoplasia, minor limb anomalies and massive dysfunction of sleep wake rhythm - a case report**  
**Dr. Lukas Gerber<sup>1</sup>**, Dr. Benno Röthlisberger<sup>1</sup>, Dr. Jens Acker<sup>2</sup>, Prof. Andreas Bock<sup>1</sup>  
<sup>1</sup>Kantonsspital Aarau, <sup>2</sup>Klinik für Schlafmedizin Zuzach, Bad Zuzach
- P 29**      **Role of the serine protease CAP2/Tmprss4 in renal adaptation to potassium depletion (NCCR project)**  
**Dr. Anna Keppner<sup>1</sup>**, Dr. Darko Maric<sup>2</sup>, Dr. Denise Kratschmar<sup>3</sup>, Dr. Petra Klusonova<sup>3</sup>, Dr. Jérémie Canonica<sup>2</sup>, Prof. Alex Odermatt<sup>3</sup>, Dr. Gilles Crambert<sup>4</sup>, Prof. David Hoogewijs<sup>5</sup>, Prof. Edith Hummler<sup>2</sup>  
<sup>1</sup>University of Lausanne and University of Fribourg, Lausanne and Fribourg, <sup>2</sup>University of Lausanne, <sup>3</sup>University of Basel, <sup>4</sup>French National Institute of Health and Medical Research (Inserm), Paris, France, <sup>5</sup>University of Fribourg
- P 30**      **Salt-sensitive hypertension in a new rat model for primary generalized glucocorticoid resistance (NCCR project)**  
**Dr. Sofia Verouti<sup>1</sup>**, Mr. David Ancín Del Olmo<sup>2</sup>, Dr. Qing Wang<sup>3</sup>, Mrs. Anne-marie Merillat<sup>4</sup>, Dr. Veronica Ponce De Leon<sup>4</sup>, Dr. Denise Kratschmar<sup>5</sup>, Prof. Alex Odermatt<sup>5</sup>, Prof. Edith Hummler<sup>4</sup>  
<sup>1</sup>Inselspital, Bern, <sup>2</sup>University of Lausanne, <sup>3</sup>Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, <sup>4</sup>University of Lausanne, <sup>5</sup>University of Basel
- P 31**      **Rebore the kidney - a novel model of back diffusion for acute shock related damage and acute tubular obstruction in anuric/oliguric kidneys: analysis from mathematical models**  
**Prof. Mark Christopher Arokiaraj<sup>1</sup>**  
<sup>1</sup>Pondicherry Institute of Medical Sciences, Pondicherry, India

## Poster presentations

- P 32**      **Aldosterone controls primary cilium length and Ift88 abundance via mineralocorticoid receptor in the distal segments of the kidney tubule \*NCCR project\***  
**Ms. Olga Komarynets<sup>1</sup>**, Dr. Eva Bernabeu-Dizin<sup>1</sup>, Dr. Jan Czogalla<sup>2</sup>, Dr. Khalil Udwan<sup>1</sup>, Ms. Alexandra Chassot<sup>1</sup>, Mr. Isabelle Roth<sup>1</sup>, Prof. Johannes Loffing<sup>2</sup>, Prof. Eric Feraille<sup>1</sup>  
<sup>1</sup>University of Geneva, <sup>2</sup>University of Zurich
- P 33**      **Identification of a novel hepatitis E virus-genotype 3 strain from a chronic hepatitis E virus infection in a kidney transplant recipient in Switzerland**  
**Dr. Agnes Kneubühl<sup>1</sup>**, Mr. Bo Wang<sup>2</sup>, Mr. Dominik Harms<sup>2</sup>, Dr. Diana Ciardo<sup>3</sup>, Prof. Jörg Hofmann<sup>4</sup>, Prof. Claus-Thomas Bock<sup>2</sup>  
<sup>1</sup>Hospital Lachen, <sup>2</sup>Robert Koch Institute, Berlin, Germany, <sup>3</sup>Corelab Immunology Viollier AG, Allschwil, <sup>4</sup>Charité, University Hospital, Berlin, Germany
- P 34**      **Renal erythropoietin producing cells in vivo (NCCR Project)**  
**Dr. Karen Nolan<sup>1</sup>**, Mr. Willy Kuo<sup>1</sup>, Dr. Faik Imeri<sup>1</sup>, Dr. Svende Pfundstein<sup>1</sup>, Dr. Irene Abreu-rodríguez<sup>1</sup>, Mr. Patrick Spielmann<sup>1</sup>, Prof. Edith Hummler<sup>2</sup>, Dr. Claus-dieter Schuh<sup>1</sup>, Prof. Andrew Hall<sup>1</sup>, Prof. Vartan Kurtcuoglu<sup>1</sup>, Dr. Carsten Scholz<sup>1</sup>, Prof. David Hoogewijs<sup>3</sup>, Prof. Roland Wenger<sup>1</sup>  
<sup>1</sup>University of Zurich, <sup>2</sup>University of Lausanne, <sup>3</sup>University of Fribourg
- P 35**      **Hypoxia-induced long non-coding RNA Malat1 is dispensible for renal ischemia/reperfusion injury**  
**Mr. Malte Kölling<sup>1</sup>**, Dr. Celina Schauerte<sup>2</sup>, Dr. Tamas Kaucsar<sup>3</sup>, Ms. Anika Hübner<sup>2</sup>, Dr. Song Rong<sup>2</sup>, Dr. Roland Schmitt<sup>2</sup>, Dr. Inga Sörensen-Zender<sup>2</sup>, Prof. Hermann Haller<sup>2</sup>, Prof. Rudolf P. Wüthrich<sup>1</sup>, Prof. Martin Zörnig<sup>4</sup>, Prof. Thomas Thum<sup>2</sup>, Prof. Johan Lorenzen<sup>1</sup>  
<sup>1</sup>University Hospital Zurich, Zurich, Switzerland, <sup>2</sup>Hannover Medical School, Hannover, Germany, <sup>3</sup>Semmelweis University, Budapest, Hungary, <sup>4</sup>Georg-Speyer-Haus, Frankfurt, Germany

## Poster presentations

- P 36**      **Anti-oxidative role of cytoglobin in podocytes and its association with chronic kidney disease (NCCR project)**  
**Dr. Elisa Randi**<sup>1</sup>, Dr. Benjamin Vervaet<sup>2</sup>, Mr. Stijn Vermeylen<sup>2</sup>, Dr. Maria Tsachaki<sup>3</sup>, Ms. Elena Porto<sup>4</sup>, Dr. Maja T. Lindenmeyer<sup>5</sup>, Dr. Clemens D. Cohen<sup>5</sup>, Prof. Thomas Hankeln<sup>4</sup>, Dr. Andreas Kistler<sup>6</sup>, Prof. Sylvia Dewilde<sup>2</sup>, Prof. Olivier Devuyst<sup>5</sup>, Prof. Alex Odermatt<sup>3</sup>, Prof. Roland Wenger<sup>5</sup>, Prof. David Hoogewijs<sup>7</sup>  
<sup>1</sup>University of Fribourg & University of Zurich, Fribourg and Zurich, <sup>2</sup>University of Antwerp, Antwerp, Belgium, <sup>3</sup>University of Basel, <sup>4</sup>University of Mainz, Mainz, Germany, <sup>5</sup>University of Zurich, <sup>6</sup>Kantonsspital Frauenfeld, <sup>7</sup>University of Fribourg
- P 37**      **Uromodulin excretion is modulated by the calcium-sensing receptor**  
**Dr. Natsuko Tokonami**<sup>1</sup>, Dr. Eric Olinger<sup>1</sup>, Prof. Pascal Houillier<sup>2</sup>, Prof. Olivier Devuyst<sup>1</sup>  
<sup>1</sup>University of Zurich, <sup>2</sup>Paris Descartes University, Paris, France
- P 38**      **The TWEAK/Fn14 pathway is required for Calcineurin Inhibitor Toxicity of the Kidneys**  
Ms. Meike Claus<sup>1</sup>, Ms. Rana Herro<sup>2</sup>, Dr. Dennis Wolf<sup>2</sup>, Dr. Konrad Buscher<sup>2</sup>, Dr. Stefan Rudloff<sup>1</sup>, Prof. Uyen Huynh-Do<sup>1</sup>, Dr. Linda Burkly<sup>3</sup>, Dr. Mick Croft<sup>2</sup>, **Dr. Daniel Sidler**<sup>1</sup>  
<sup>1</sup>University Hospital Bern, <sup>2</sup>La Jolla Institute for Allergy and Immunology, La Jolla, United States, <sup>3</sup>Biogen, Boston, United States
- P 39**      **Bone marrow transplantation improves proximal tubule dysfunction in mouse models of Dent disease**  
**Mr. Alkaly Gassama**<sup>1</sup>, Ms. Beatrice Paola Festa<sup>1</sup>, Dr. Sarah Gabriel<sup>2</sup>, Dr. Alessandro Luciani<sup>1</sup>, Prof. Thomas Fehr<sup>3</sup>, Prof. Olivier Devuyst<sup>1</sup>  
<sup>1</sup>University of Zurich, <sup>2</sup>University of Melbourne, Victoria, Australia, <sup>3</sup>Kantonsspital Graubünden, Chur

## Poster presentations

### Hemodialysis / Peritoneal Dialysis

- P 40**      **ionized and total serum magnesium in hemodialysis: predictors and variability. a longitudinal cross-sectional study**  
**Dr. Rosaria Del Giorno**<sup>1</sup>, Dr. Hilary Riva<sup>2</sup>, Mr. Gaetano Lucio Donato<sup>3</sup>, Prof. Luca Gabutti<sup>3</sup>  
<sup>1</sup>EOC Bellinzona, <sup>2</sup>EOC Mendrisio, <sup>3</sup>EOC Locarno
- P 41**      **Clostridium ramosum - a rare cause of peritoneal dialysis related peritonitis**  
**Mrs. Jennifer Scotti Gerber**<sup>1</sup>, Dr. Linda Berney-Meyer<sup>2</sup>, Prof. Stephan Segerer<sup>3</sup>  
<sup>1</sup>EOC Lugano, <sup>2</sup>Universitätsspital Zürich, <sup>3</sup>Kantonsspital Aarau
- P 42**      **Is there a mortality paradox among diabetic patients within the Swiss dialysis population ?**  
**Ms. Rebecca Winzeler**<sup>1</sup>, Prof. Patrice M. Ambühl<sup>1</sup>  
<sup>1</sup>Stadtspital Waid, Zurich
- P 43**      **Demography of the dialysis population in Switzerland**  
**Ms. Rebecca Winzeler**<sup>1</sup>, Prof. Patrice M. Ambühl<sup>1</sup>  
<sup>1</sup>Stadtspital Waid, Zurich
- P 44**      **Evaluation of the relationship between muscle mass and serum myo- statin levels in chronic hemodialysis patients**  
**Dr. Derya Koyun**<sup>1</sup>, Prof. Gokhan Nergizoglu<sup>1</sup>, Prof. Kemal Metin Kir<sup>1</sup>  
<sup>1</sup>Ankara University School Of Medicine, Ankara, Turkey
- P 45**      **Prolonged disease-free survival after treatment of a bilateral breast granulocytic sarcoma with low-dose sorafenib in a chronic hemodialyzed patient**  
**Ms. Julie Robert**<sup>1</sup>, Dr. Ould Maouloud Hemett<sup>1</sup>, Dr. Merryl Cassat<sup>1</sup>, Dr. Gaëlle Rhyner<sup>1</sup>, Dr. Eric Descombes<sup>1</sup>, Prof. Daniel Betticher<sup>1</sup>  
<sup>1</sup>HFR, Hopital Cantonal de Fribourg
- P 46**      **Safety first, fistula second!**  
**Dr. Sandra Edith Knych**<sup>1</sup>, Dr. Georg-Wilhelm Meier-Fiorese<sup>1</sup>, Dr. Felix Burkhalter<sup>1</sup>  
<sup>1</sup>Kantonsspital Baselland, Liestal

## Poster presentations


### Transplantation

- P 47**      **Role of Immune-Senescence in the development of de-novo Donor-Specific Antibodies after Kidney Transplantation**  
**Dr. Seraina von Moos**<sup>1</sup>, Dr. Gesa Schalk<sup>2</sup>, Dr. Guido F. Laube<sup>2</sup>, Prof. Thomas Mueller<sup>1</sup>  
<sup>1</sup>Universitätsspital Zürich, <sup>2</sup>Universitäts Kinderspital Zürich
- P 48**      **Postoperative Seroma after Kidney Transplantation: Identification of donor-, recipient- and procedure-associated risk factors**  
Mr. Ruhin Parsa<sup>1</sup>, Dr. Spiridon Arampatzis<sup>1</sup>, Dr. Guido Beldi<sup>1</sup>, Dr. Suzan Dahdal<sup>1</sup>, Ms. Angela Buechel<sup>1</sup>, Prof. Bruno Vogt<sup>1</sup>, Prof. Uyen Huynh-Do<sup>1</sup>, Dr. Vanessa Banz<sup>1</sup>, **Dr. Daniel Sidler**<sup>1</sup>  
<sup>1</sup>University Hospital Bern
- P 49**      **Safety of Early RAS Blockade in Kidney Transplant Recipients**  
Mr. Luca Valente<sup>1</sup>, Dr. Spiridon Arampatzis<sup>1</sup>, Dr. Mariam Semmo<sup>1</sup>, Prof. Bruno Vogt<sup>1</sup>, Prof. Uyen Huynh-Do<sup>2</sup>, **Dr. Daniel Sidler**<sup>1</sup>  
<sup>1</sup>University Hospital Bern, <sup>2</sup>Inselspital Bern
- P 50**      **Antibody-mediated rejection triggered by parvovirus B19 infection? A case report**  
**Dr. Melanie Schönenberger**<sup>1</sup>, Dr. Patricia Hirt-Minkowski<sup>1</sup>, Dr. Helmut Hopfer<sup>1</sup>, Dr. Thomas Menter<sup>1</sup>, Prof. Stefan Schaub<sup>1</sup>, Dr. Katrin König<sup>1</sup>  
<sup>1</sup>University Hospital Basel 1
- P 51**      **Transplant Glomerulopathy and Arteriolo-hyalinosis in Renal Allograft Biopsies: Correlation between Histopathology and Clinical Outcome**  
Mr. Jannick Schneuwly<sup>1</sup>, Dr. Vera Genitsch<sup>2</sup>, Prof. Bruno Vogt<sup>1</sup>, Prof. Uyen Huynh-Do<sup>1</sup>, **Dr. Daniel Sidler**<sup>1</sup>  
<sup>1</sup>University Hospital Bern, <sup>2</sup>University of Bern
- P 52**      **Relationship of serum bicarbonate levels with 1-year graft function in kidney transplant recipients**  
**Ms. Anna Wiegand**<sup>1</sup>, Dr. Nicole Graf<sup>2</sup>, Dr. Marco Bonani<sup>1</sup>, Dr. Diana Frey<sup>1</sup>, Prof. Rudolf P. Wüthrich<sup>1</sup>, Dr. Nilufar Mohebbi<sup>1</sup>  
<sup>1</sup>University Hospital Zurich, <sup>2</sup>Graf Biostatistics, Winterthur

## Poster presentations

- P 53**      **Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study)**  
Ms. Anna Wiegand<sup>1</sup>, **Dr. Alexander Ritter**<sup>1</sup>, Dr. Nicole Graf<sup>2</sup>, Dr. Karine Hadaya<sup>3</sup>, Dr. Spyridon Arampatzis<sup>4</sup>, Prof. Thomas Mueller<sup>1</sup>, Prof. Carsten Wagner<sup>5</sup>, Prof. Rudolf P. Wüthrich<sup>1</sup>, Dr. Nilufar Mohebbi<sup>1</sup>  
<sup>1</sup>University Hospital Zurich, <sup>2</sup>Graf Biostatistics, Winterthur, <sup>3</sup>Geneva University Hospitals, <sup>4</sup>Inselspital Bern, <sup>5</sup>University of Zurich
- P 54**      **The humoral long-term progression of kidney function in patients with and without humoral allograft response**  
**Dr. Seraina von Moos**<sup>1</sup>, Dr. Pietro E. Cippà<sup>2</sup>, Mr. Robert Van Breemen<sup>1</sup>, Prof. Thomas Mueller<sup>1</sup>  
<sup>1</sup>Universitätsspital Zürich, <sup>2</sup>University of Southern California, Los Angeles, United States
- P 55**      **Rituximab induces “false” positive complement-dependent cytotoxic B cells crossmatches**  
**Dr. Karine Hadaya**<sup>1</sup>, Mr. Johan Geiser<sup>2</sup>, Prof. Thierry Berney<sup>2</sup>, Prof. Pierre-Yves Martin<sup>3</sup>, Prof. Jean Villard<sup>2</sup>, Dr. Sylvie Ferrari-Lacraz<sup>2</sup>  
<sup>1</sup>Geneva University Hospitals, <sup>2</sup>Geneva University Hospital and Medical School, <sup>3</sup>AMC/Geneva University Hospitals
- P 56**      **Activability of circulating Tfh17 predicts humoral response to thymus-dependent antigens**  
**Dr. Suzan Dahdal**<sup>1</sup>, Ms. Carole Saison<sup>1</sup>, Dr. Martine Valette<sup>2</sup>, Prof. Bruno Lina<sup>3</sup>, Prof. Guillaume Monneret<sup>4</sup>, Dr. Thierry Defrance<sup>5</sup>, Prof. Emmanuel Morelon<sup>6</sup>, Prof. Olivier Thaunat<sup>4</sup>  
<sup>1</sup>French National Institute of Health and Medical Research (Inserm) Unit 1111, Lyon, France, <sup>2</sup>Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France, <sup>3</sup>Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France, <sup>4</sup>Hospices Civils de Lyon, Edouard Herriot University Hospital, Lyon, France, <sup>5</sup>French National Institute of Health and Medical Research (Inserm), Lyon, France, <sup>6</sup>Hospices Civils de Lyon, Edouard Herriot University Hospital, Department of Transplantation, Lyon, France

# Plan of exhibition



# Exhibitors

Company	Booth
Abbvie AG	19
AIRG	3B
Alexion Pharma GmbH	23
Amgen Switzerland AG	24
Astellas Pharma AG	5
Baxter AG	17
B. Braun Medical AG	10
Bracco Suisse SA	7
CytoSorbents Switzerland GmbH	18
Diavantis	4C
Forni medical gmbh	13
Fresenius Medical Care (Schweiz) AG	24
Laboratorium Dr G. Bichsel AG	21
MCM MEDSYS AG	4B
medi-lan ag	22
Mitsubishi Tanabe Pharma GmbH	16
Neovii Pharmaceuticals AG	4A
Novartis Pharma Schweiz AG	15
Otsuka Pharmaceutical (Switzerland) GmbH	1
Pro Farma AG	11
Roche Pharma (Schweiz) AG	8
Salmon Pharma GmbH	12
Sandoz Pharmaceuticals AG	15
sanofi-aventis (schweiz) ag	14
Schweizer Dialyseregister	3A
Shire Switzerland GmbH	25
Terumo BCT Europe N.V.	6
theramed ag	20
Vifor SA	9/2B
VNPS	3C



## Speakers / Moderators

Ambühl Patrice, Zürich  
Amico Patrizia, Basel  
Arampatzis Spyridon, Bern  
Bichet Daniel G., Montreal (CA)  
Bock Andreas, Aarau  
Bonny Olivier, Lausanne  
Burnier Michel, Lausanne  
De Seigneux Sophie, Geneva  
De Zélicourt Diane, Zürich  
Devuyst Olivier, Zürich  
Dickenmann Michael, Basel  
Dufey-Teso Anne, Geneva  
Ernandez Thomas, Geneva  
Ferrari Paolo, Lugano/Sydney (AU)  
Fischer Andreas, Lucerne  
Fuster Daniel, Bern  
Gabutti Luca, Locarno  
Gaspert Ariana, Zürich  
Genitsch-Gratwohl Vera, Bern  
Goffin Eric, Bruxelles (BE)  
Hadaya Karine, Geneva  
Halabi Georges, Lausanne  
Hamer Rizwan, Coventry (GB)  
Hayoz Daniel, Fribourg  
Helary Christiane, Geneva  
Helou Nancy, Lausanne  
Hopfer Helmut, Basel  
Huynh-Do Uyen, Bern  
Jotterand Drepper Valérie, Geneva  
Kistler Andreas, Frauenfeld  
Kurschat Christine, Köln (DE)  
Kuypers Dirk, Leuven (BE)  
Lambie Mark, Stokes (GB)  
Lefuel Pascale, Geneva  
Loffing Johannes, Zürich  
Lorenzen Johan, Zürich  
Martin Pierre-Yves, Geneva  
Menter Thomas, Basel  
Mohebbi Nilufar, Zürich  
Moll Solange, Geneva  
Müller Thomas, Zürich  
Nobre Dina, Lausanne  
Pascual Manuel, Lausanne  
Ponte Belen, Geneva  
Pruijm Menno, Lausanne  
Ricklin Daniel, Basel  
Rotman Samuel, Lausanne  
Scholz Carsten, Zürich  
Schwarz Albin, Zürich  
Seron Daniel, Barcelona (ES)  
Stoermann-Chopard Catherine, Geneva  
Stucker Fabien, Neuchâtel  
Tschumi Sibylle, Bern  
Uehlinger Dominik, Bern  
Villard Jean, Geneva  
Wagner Carsten, Zürich  
Würzner Grégoire, Lausanne  
Zeerleder Sacha, Amsterdam (NL)

## Association

Association pour l'Information et la Recherche sur les maladies rénales Génétiques (AIRG)



Verband Nierenpatienten Schweiz (VNPS)

*Kind thanks to the municipality of Granges-Paccot, as well as to the State of Fribourg, for their financial support and welcome*



ETAT DE FRIBOURG  
STAAT FREIBURG



## Sponsored in alphabetical order

**Symposia**

**AMGEN**

**Amgen Switzerland AG**

Satellite Symposium

Thursday, December 7, 2017 – 12.30-13.15/Room A

**astellas**

**Astellas Pharma AG**

Satellite Symposium

Friday, December 8, 2017 – 12.30-13.15/Room A

**Baxter**

**Baxter AG**

Parallel Satellite Symposium

Thursday, December 7, 2017 – 15.30-16.15/Room A

**Otsuka**

**Otsuka Pharmaceutical (Switzerland) GmbH**

Parallel Satellite Symposium

Thursday, December 7, 2017 – 15.30-16.15/Room B

**VIFOR PHARMA**

**Vifor SA**

Satellite Symposium

Friday, December 8, 2017 – 10.15-11.00/Room A

## Lectures

It is a support of a 30-minute session based on the scientific program, the sponsor has no influence neither on the content nor on the choice of the speakers (responsibility of the SSN)

**ALEXION**

**Alexion Pharma GmbH**

Sponsored lecture

Thursday, December 7, 2017 – 14.00-15.00/Room A

**Baxter**

**Baxter AG**

Sponsored lecture

Friday, December 8, 2017 – 11.30-12.15/Room A

**Shire**

**Shire Switzerland GmbH**

Sponsored lecture

Thursday, December 7, 2017 – 17.10-17.40/Room B

## Advertisement

sanofi-aventis (schweiz) ag

## Kind thanks to all our sponsors

abbvie

**AIRG** Suisse  
Association pour l'Information  
et la Recherche sur les maladies  
rénales Génétiques

**ALEXION**

**AMGEN**

**astellas**

**Amicus**  
Therapeutics

**Baxter**

**B | BRAUN**  
SHARING EXPERTISE

90  
**BRACCO**  
anniversary

**CytoSorbents**

*fm* forni medical gmbh

**DIAVANTIS**

**bichsel**

**FRESENIUS**  
**MEDICAL CARE**

**MCM MEDSYS**  
Together to excellence

medilán

**MEDLINE**

## Kind thanks to all our sponsors

**NephroFlow**<sup>®</sup>

 Mitsubishi Tanabe Pharma GmbH

**neovii**

 **NOVARTIS**

  
Otsuka

  
**PRO FARMA**

  
**Roche**

Salmon Pharma  
Ein Unternehmen der  
  
**MEDICE**

**SANDOZ** A Novartis  
Division

  
**Shire**

  
**SANOFI**

  
**SANOFI GENZYME**

  
swiss renal registry and quality assessment program

**TERUMOBCT**  
Unlocking the Potential of Blood

  
**theramed ag**  
medizinprodukte

 **VIFOR  
PHARMA**

## Save the date: SGN-SSN congress 2018

We would like to invite you to the

**50th Annual Meeting** of the Swiss Society of Nephrology SGN-SSN  
on **December 6-7, 2018** – Congress Centre Kursaal Interlaken



**Please save the dates of December 6-7, 2018!**

We look forward to welcoming you in Interlaken next year!

**NEPHRO**  
SWISS SOCIETY OF NEPHROLOGY  
[www.swissnephrology.ch](http://www.swissnephrology.ch)

Schweizerische Gesellschaft für Nephrologie  
Société Suisse de Néphrologie  
Società Svizzera di Nefrologia

# RENVELA®

Your partner against hyperphosphatemia<sup>1</sup>



Calcium-free



Metal-free\*



Not absorbed\*\*

## Right from the start.

**RenVela**  
Sevelamercarbonat

<sup>1</sup> Active substance without metals or calcium. Sevelamer carbonate is a polymer that is not absorbed in the gastrointestinal tract.  
<sup>\*\*</sup> In a one-year clinical study, no evidence of sevelamer accumulation was found.

**Renvela®** Film-coated tablets 800 mg and powder 2.4 g. **DS:** Sevelamer carbonate. **E:** Adults: hyperphosphatemia in patients undergoing haemodialysis or peritoneal dialysis and nonhaemodialysis-dependent patients with chronic renal insufficiency and serum phosphorus levels of  $\geq 1.75$  mmol/L. For use in multipart treatment. **D:** 2.4 g or 4.8 g per day (initial dose) spread over three meals. Average approx. 6 g/day with continuous treatment. Drink suspension within 30 minutes of preparation. **CE:** Hypersensitivity to an active substance, hypophosphatemia, bowel obstruction. **WP:** Children and adolescents under 18 years of age, non-haemodialysis-dependent patients with chronic renal insufficiency and serum phosphorus level  $< 1.75$  mmol/L, patients with dyspepsia, peptic ulcers, severe gastrointestinal motility dysfunction (including untreated or severe gastroparietic, retention of stomach content and abnormal or irregular bowel movement), active inflammatory bowel disease, major surgery on the gastrointestinal tract, obstruction bowel occlusion, ileus/prolapse, reduced absorption of liposoluble vitamins (A, D, E and K), folate deficiency, hypo-/hypercalcemia, metabolic acidosis, pyelitis, simultaneous use of anticholinergic and antidiabetic drugs, hypothyroidism, long-term chronic treatment (>3 year) with sevelamer, hyperparathyroidism. **IA:** Reduced calciparine, erythropoietin and heparin levels in transplant patients. Monitor TSH level when administering levothyroxine. Particular caution is required with patients using antiepileptic or antiarrhythmic drugs. Renvela is not absorbed and can affect the bioavailability of other drugs. There are no to be given at least one hour before or three hours after Renvela. **SE:** very common: nausea, vomiting, pain in the upper abdomen, obstruction; frequent: diarrhoea, dyspepsia, flatulence, stomach pain. **PS:** Renvela Film-coated tab., 800 mg tbl., 180 pcs. Renvela powder 2.4 g pouch 60 pcs. **Med. class:** B. **MAH:** Sanofi-Aventis (Switzerland) AG, 1214 Venney/GS. **Updated:** Film-coated tablets: March 2017, powder: March 2017 (SACH.SEC.17.09.0511). For further specialised information please visit [www.swissmedinfo.ch](http://www.swissmedinfo.ch).